In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ilypsa raises $36mm with Series B venture round

Executive Summary

Biopharmaceutical company Ilypsa (formerly Symyx Therapeutics, a 2003 spin-out from Symyx Technologies) raised $36mm in a Series B round co-led by new investors US Venture Partners, Johnson & Johnson Development Corp., and Delphi Ventures. Also participating in the financing were other new investors CMEA Ventures and Mediphase Venture Partners, along with existing backers Sprout Group and 5AM Ventures.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies